Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine

Debra J. Hendrickson, Dean A Blumberg, Jesse P. Joad, Sanjay Jhawar, Ruth J McDonald

Research output: Contribution to journalArticle

68 Scopus citations

Abstract

A retrospective review of medical records for all pediatric parapneumonic empyema (PPE) patients admitted to our hospital from 1996 to 2006 revealed that PPE increased 5-fold in the post-heptavalent pneumococcal conjugate vaccine (PCV7) period (2001-2005) relative to the pre-PCV7 period (1996-2000), from 13 cases to 65. Most of this increase was associated with culture-negative empyema, which accounted for 61% of all post-2000 cases; 19% was culture-positive pneumococcal empyema. Our analysis indicates that non-PCV7 serotypes became more prevalent at our institution after introduction of the vaccine.

Original languageEnglish (US)
Pages (from-to)1030-1032
Number of pages3
JournalPediatric Infectious Disease Journal
Volume27
Issue number11
DOIs
StatePublished - Nov 2008

Keywords

  • Empyema, invasive disease
  • Pneumococcal vaccine
  • Pneumococcus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine'. Together they form a unique fingerprint.

  • Cite this